Zynex, Inc. announced it has been awarded UK patent 2617515 for a multiparameter, noninvasive sepsis monitor. Sepsis is a life-threatening condition characterized by systemic inflammation and organ dysfunction, with over half of cases contracted in hospitals and a high mortality rate due to detection difficulties. Globally, sepsis kills 11 million people annually, accounting for roughly 20% of global deaths.
The envisioned device aims to continuously monitor multiple physiological signals, providing early alerts to clinicians about a patient's trends and sepsis status. Early detection and treatment are vital for patient recovery, as highlighted by the Surviving Sepsis Campaign. Late diagnosis leads to higher economic burdens and increased mortality rates.
Thomas Sandgaard, Founder and CEO of Zynex, stated that the company has an opportunity to develop a noninvasive, highly accurate monitor that can drastically reduce sepsis mortality. Donald Gregg, President of Zynex Monitoring Solutions, added that this product would be derived from their growing portfolio of noninvasive monitoring technologies, contributing significantly to earlier detection of this deadly condition.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.